Iterum Therapeutics (NASDAQ:ITRM) focuses on developing and commercializing drugs to treat infections caused by multi-drug resistant pathogens. A significant project in their portfolio is Sulopenem, an antibiotic designed to combat the rising threat of such infections, particularly in the urinary tract and the intra-abdominal region. The company's objective is to address the critical need for new antibiotics that can effectively treat resistant bacterial infections, aiming to improve outcomes for patients facing limited treatment options. Originally based in Ireland, Iterum Therapeutics is dedicated to innovation in the antibiotic space, seeking to make a meaningful difference in public health on a global scale.